^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KF-0210

    i
    Other names: KF-0210, KF-0210-0
    Associations

    News

    Trials
    Company:
    Keythera Pharma
    Drug class:
    PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=14, Completed, Keythera Pharmaceuticals (Australia) Pty Ltd | Recruiting --> Completed | N=64 --> 14
    Trial completion • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • KF-0210
    almost5years
    A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=64, Recruiting, Keythera Pharmaceuticals (Australia) Pty Ltd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • KF-0210
    almost5years
    A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, Keythera Pharmaceuticals (Australia) Pty Ltd
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • KF-0210